| Author/year |
n |
|
Hypertrophy |
Morbidity ≥IIIb (%) |
90 days mortality (%) |
RO resection |
| Santibanes a kol2012 [2] |
15 |
NA |
78% (21-139%) |
53% |
0% |
NA |
| Torres a kol2013 [10] |
39 |
CRLM 32 |
83% (47-212%) |
59% |
13% |
100% |
| CC 9 |
|
|
|
|
| sarcom 2 |
|
|
|
|
| HCC 1 |
|
|
|
|
| benign 1 |
|
|
|
|
| Schnitzbauer a kol2012 [9] |
25 |
CRLM 14 |
74% (21-192%) |
68% |
12% |
96% |
| HCC 4 |
|
|
|
|
| CC 4 |
|
|
|
|
| GB 1 |
|
|
|
|
| other 3 |
|
|
|
|
| Li Jun a kol 2012 [14] |
9 |
CRLM 9 |
87% (24-161%) |
68% |
12% |
33% |
| CC 6 |
|
|
|
|
| Knoefel a kol2013 [6] |
7 |
NA |
63% |
71% |
0% |
NA |
| Schadde et al. 2014 [F] |
202 |
CRLM 141 |
80% |
28 |
9% |
91% |
| HCC 17 |
|
|
|
|
| CC 19 |
|
|
|
|
| NET 8 |
|
|
|
|
| GB 6 |
|
|
|
|
| Other 11 |
|
|
|
|
| Robles et al.2014 |
22 |
CRLM 17 |
61% |
9% |
9% |
100% |
| RCC 2 |
|
|
|
|
| HCC 1 |
|
|
|
|
| GIST 1 |
|
|
|
|
| NET 1 |
|
|
|
|
| Nadalin et al. 2014
|
15
|
CRLM 5 |
87% |
NA |
10% |
87% |
| CC 9 |
|
|
|
|
| HCC1 |
|
|
|
|
| Alvarez et al. 2013 |
15 |
CRLM 10 |
78% |
27% |
0% |
100% |
| HCC 1 |
|
|
|
|
| CC 1 |
|
|
|
|
| NET 2 |
|
|
|
|
| Other 2 |
|
|
|
|
| Hernandez et al. 2014 |
14 |
CRLM 14 |
93% |
14% |
0% |
86% |
| Sala et al. 2012 |
10 |
CRLM 7 |
82% |
0% |
0% |
100% |
|